VIR — Vir Biotechnology, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1706431 ·
Last close
$9.25
Market Cap
$1.58B
52W High
$14.38
52W Low
$5.32
ADV30
2,697,368
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 -200,000 -200,000 -104,658,000 -96,252,000 1,111,855,000 218,866,000 215,819,000
Jun 2026 238,935,000 238,935,000 73,467,000 80,080,000 1,214,806,000 278,729,000 232,313,000
Mar 2026 -41,000 — -132,290,000 -125,695,000 1,025,585,000 274,161,000 212,820,000
Dec 2025 63,760,000 63,734,000 -47,921,000 -42,923,000 1,002,823,000 232,185,000 237,547,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-141,017,000
Investing CF
$-54,097,000
Financing CF
$243,572,000
CapEx
$-804,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.26
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,339,638,000
Inventory
—
Receivables
—
ST Investments
$239,491,000
EBIT TTM
$-211,402,000
Pretax Income TTM
$-184,721,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$302,799,008
EBITDA
$-201,320,992
Free Cash Flow
$-81,924,248
Enterprise Value
$1,723,634,176
Total Cash
$458,356,992
Total Debt
$90,775,000
Shares Out
171,270,773
Trailing EPS
$-1.18
Book Value
$5.29
ROE
-21.8%
ROA
-12.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 66,520,000 -479,510,000 -437,987,000 1,002,823,000 237,547,000 765,276,000 -391,781,000
Dec 2024 63,712,000 -552,170,000 -521,960,000 1,398,813,000 248,428,000 1,150,385,000 -446,352,000
Dec 2023 39,494,000 -670,746,000 -615,061,000 1,919,060,000 328,824,000 1,590,236,000 -778,785,000
Dec 2022 1,580,472,000 833,068,000 515,837,000 2,802,088,000 724,125,000 2,077,963,000 1,663,253,000

TTM Snapshot

Revenues TTM
$303,227,000
NetIncome TTM
$-251,679,000
OpCashFlow TTM
—
Assets (Latest)
$1,214,806,000
Forward EPS
$-2.32

Max Pain — expiry 2027-01-15

max pain strike: $9.00 · spot: $9.15 · call oi: 6,313 · put oi: 421
Expected Move to 2027-01-15: ±$2.50 (27.32%) — implied range $6.65 – $11.65 · ATM straddle on $9.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALVO Alvotech $1.56B $4.37 —
LYCA Lycia Therapeutics, Inc. $1.61B $30.92 —
MESO MESOBLAST LTD $1.55B $11.91 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —
MEOBF MESOBLAST LTD $1.48B $1.14 —

News headlines (Yahoo Finance, 1h cache)

Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale
2026-11-13 17:14 · Yahoo
Vir Biotechnology stock tumbles on $150M share offering
2026-11-13 14:57 · Yahoo
Sector Update: Healthcare Stocks Rise Pre-Bell Friday
2026-11-13 14:16 · Yahoo
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
2026-11-13 00:38 · Yahoo
Vir Biotechnology Announces Proposed Public Offering
2026-11-12 21:08 · Yahoo
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
2026-11-10 14:12 · Yahoo
Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
2026-11-10 10:17 · Yahoo
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
2026-11-09 20:07 · Yahoo
Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints
2026-11-09 19:13 · Yahoo
Vir hepatitis D drug succeeds in first pivotal study
2026-11-09 17:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.